Cheryl Cohen, National Institute for Communicable Diseases dan Sibongile Walaza, University of the Witwatersrand
Digital participatory surveillance allows the community to share in the responsibility of disease surveillance and contribute to the control and prevention of respiratory disease outbreaks.
Many patients suffering from COVID-19 exhibit neurological symptoms, from loss of smell to delirium to a higher risk of stroke. Down the road, will COVID-19 survivors face a wave of cognitive issues?
Dangerous delays may happen at three points: the patient deciding to seek care, reaching a healthcare facility, or receiving quality care at that facility.
Is it possible that people who recover from COVID-19 will be plagued with long term side effects from the infection? An infectious disease physician reviews the evidence so far.
S. pneumoniae, the bacteria responsible for pneumonia, causes about one million deaths each year. Now we know how it uses the sugar raffinose to spread through the body to cause disease.
Who is most likely to survive an infection of the new coronavirus? Two immunologists explain that it is those who mount exactly the right immune response – not too weak, not too strong.
Two phrases you hear a lot these days are viral load and infectious dose. What do they mean? Do they reflect the severity of disease or whether someone will get severely ill? Two experts explain.
Ririn Ramadhany, National Institute of Health Research and Development (NIHRD), Ministry of Health Indonesia
Genetic analysis indicates novel coronavirus from Wuhan has a 89% similarity to the SARS virus, a relative of the SARS bat virus. However this does not mean nCoV comes from bats.
The bacteria that causes melioidosis usually lives 30cm underground in clay soil but is dredged to the surface during heavy rains and floods, and can enter the body through small breaks in the skin.
Nicole Wolter, National Institute for Communicable Diseases
There have been many advances made in the prevention and treatment of pneumonia, but providing for people’s basic needs can help reduce the disease burden.
By committing ourselves to understanding how interventions work on the ground, we have the opportunity to save the millions who die unnecessarily each and every year.
Director, Evidence and Methods, National COVID-19 Clinical Evidence Taskforce; Associate Professor (Research), Cochrane Australia, School of Population Health and Preventive Medicine, Monash University